The purpose of this study is to assess the early bacterial activity (EBA) from day 0 to day
14 of Astra Zeneca Drug (AZD5847) at four different doses and schedules (500 mg once daily,
500 mg twice daily, 1200 mg once daily, and 800 mg twice daily) in subjects with
newly-diagnosed sputum smear positive pulmonary TB. A total of 75 subjects will be enrolled,
with 15 randomized to each AZD5847 study arm or standard treatment with Rifafour. Duration of
drug treatment is 14 days.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)